CoChat
Sign Up
Cited by 42Metabolomics and Mass Spectrometry StudiesLiver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

The DOI matches its Crossref record; its reference list is not available.

Changes in human hepatic metabolism in steatosis and cirrhosis

Open access
Schofield, Zoe, Reed, Michelle AC, Newsome, Philip N, Adams, David H, Günther, Ulrich L, Lalor, Patricia F·2017·World Journal of Gastroenterology
DOI 10.3748/wjg.v23.i15.2685PMC PMC5403747
Open this paper in CoChat — free accountOpen PDF

Abstract

AIM: To understand the underlying metabolic changes in human liver disease we have applied nuclear magnetic resonance (NMR) metabolomics analysis to human liver tissue. METHODS: H-NMR to derive metabolomic signatures from human liver from patients with steatosis, nonalcoholic steatohepatitis (NASH) or alcohol-related liver damage (ARLD) to identify species that can predict outcome and discriminate between alcohol and metabolic-induced liver injuries. RESULTS: Changes in branched chain amino acid homeostasis, tricarboxylic acid cycle and purine biosynthesis intermediates along with betaine were associated with the development of cirrhosis in both ARLD and nonalcoholic fatty liver disease. Species such as propylene glycol and as yet unidentified moieties that allowed discrimination between NASH and ARLD samples were also detected using our approach. CONCLUSION: Our high throughput, non-destructive technique for multiple analyte quantification in human liver specimens has potential for identification of biomarkers with prognostic and diagnostic significance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3748/wjg.v23.i15.2685

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Succinic acid is significantly increased in feces, serum, and liver tissue from MAFLD patients.

    “Alistipes can produce succinic acid (Liu et al., 2016), which is significantly increased in feces, serum, and liver tissue from MAFLD patients (Loomba et al., 2017; Schofield et al., 2017).”

    From Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Schofield et al., 2017

    The Results (page not specified) report significantly elevated succinate in liver tissue associated with NASH, supporting the liver-tissue portion of the claim. The Discussion (page not specified) mentions increased plasma succinate in mouse models and reduced fecal excretion in insulin-resistant rats, not significant increases in serum or feces from MAFLD patients. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 54 · Cited by 42

Research works printed but not linked: 53

  1. 10.1016/j.jhep.2012.12.005 · DOI
  2. 10.1016/j.jhep.2015.02.041 · DOI
  3. Kojima H, Sakurai S, Uemura M, Takekawa T, Morimoto H, Tamagawa Y, Fukui H. Difference and similarity between non-alcoholic steatohepatitis and alcoholic liver disease. Alcohol Clin Exp Res 2005;29:259S-263S. · DOI
  4. 10.1002/hep.21763 · DOI · Paper page
  5. 10.1152/ajpendo.00161.2015 · DOI
  6. 10.1021/pr400702d · DOI
  7. 10.1039/c3mb70618d · DOI
  8. 10.1155/2014/169216 · DOI
  9. 10.3748/wjg.v21.i24.7529 · DOI
  10. Mazurek S, Shoshan M. Tumor Cell Metabolism. Springer Vienna, 2015. . · DOI
  11. 10.1016/j.ab.2007.10.002 · DOI
  12. 10.1186/1471-2105-12-366 · DOI
  13. 10.1006/jmre.2000.2071 · DOI
  14. 10.1093/nar/gks1065 · DOI
  15. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438. · DOI · Paper page
  16. 10.1002/hep.20920 · DOI · Paper page
  17. 10.1016/j.metabol.2010.03.006 · DOI · Paper page
  18. 10.1021/pr200047c · DOI
  19. 10.1007/s00726-014-1894-9 · DOI
  20. 10.4254/wjh.v7.i12.1701 · DOI
  21. 10.1002/hep.510240614 · DOI
  22. Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976;80:77-91.
  23. Mager DR, Wykes LJ, Roberts EA, Ball RO, Pencharz PB. Mild-to-moderate chronic cholestatic liver disease increases leucine oxidation in children. J Nutr 2006;136:965-970. · DOI
  24. McCullough AJ, Mullen KD, Kalhan SC. Body cell mass and leucine metabolism in cirrhosis. Gastroenterology 1992;102:1325-1333. · DOI
  25. Tessari P, Inchiostro S, Barazzoni R, Zanetti M, Orlando R, Biolo G, Sergi G, Pino A, Tiengo A. Fasting and postprandial phenylalanine and leucine kinetics in liver cirrhosis. Am J Physiol 1994;267:E140-E149. · DOI
  26. Nakanishi C, Doi H, Katsura K, Satomi S. Treatment with L-valine ameliorates liver fibrosis and restores thrombopoiesis in rats exposed to carbon tetrachloride. Tohoku J Exp Med 2010;221:151-159. · DOI
  27. Schauder P, Schröder K, Herbertz L, Langer K, Langenbeck U. Evidence for valine intolerance in patients with cirrhosis. Hepatology 1984;4:667-670. · DOI
  28. Teran JC, Mullen KD, McCullough AJ. Glutamine--a conditionally essential amino acid in cirrhosis? Am J Clin Nutr 1995;62:897-900. · DOI
  29. 10.12659/MSM.892312 · DOI
  30. 10.1002/hep.25694 · DOI
  31. 10.1002/hep.23033 · DOI
  32. 10.1158/0008-5472.CAN-13-0308 · DOI
  33. 10.1002/hep.21107 · DOI · Paper page
  34. 10.1152/ajpgi.00133.2007 · DOI
  35. 10.3748/wjg.v17.i32.3663 · DOI
  36. 10.1002/nbm.3072 · DOI
  37. 10.1016/j.bbrc.2015.06.023 · DOI
  38. 10.3109/00365513.2013.773591 · DOI
  39. Orii R, Sugawara Y, Hayashida M, Yamada Y, Kubota K, Takayama T, Harihara Y, Makuuchi M, Hanaoka K. Peri-operative blood lactate levels in recipients of living-related liver transplantation. Transplantation 2000;69:2124-2127. · DOI
  40. 10.1002/hep.510240536 · DOI
  41. 10.1007/s10522-007-9112-8 · DOI
  42. Sharma R, Dey S, Verma R. Age-specific development of malate-aspartate shuttle in the liver and kidney of mice. Biochem Int 1992;27:1059-1066.
  43. 10.1194/jlr.M034249 · DOI
  44. 10.1038/srep03459 · DOI
  45. 10.1002/mnfr.201200077 · DOI
  46. 10.1186/1742-4682-3-40 · DOI
  47. 10.1002/jcph.24 · DOI
  48. Thomsen MS, Loft S, Roberts DW, Poulsen HE. Cytochrome P4502E1 inhibition by propylene glycol prevents acetaminophen (paracetamol) hepatotoxicity in mice without cytochrome P4501A2 inhibition. Pharmacol Toxicol 1995;76:395-399. · DOI
  49. 10.1016/j.jnutbio.2012.01.008 · DOI
  50. 10.1039/c6mb00420b · DOI
  51. 10.1111/j.1463-1326.2011.01403.x · DOI
  52. 10.1096/fj.201600914R · DOI
  53. 10.3748/wjg.v19.i35.5897 · DOI

Metadata

Authors
Schofield, Z., Reed, M. A., Newsome, P. N., Adams, D. H., Günther, U. L., & Lalor, P. F.
Affiliations
Engineering and Physical Sciences Research Council (GB)
ORCID
Venue
World Journal of Gastroenterology
Publisher
Baishideng Publishing Group Inc.
Published
2017
Volume
23
Issue
15
Pages
2685
ISSN
1007-9327 (ISSN-L)
DOI
10.3748/wjg.v23.i15.2685
PMC
PMC5403747
OpenAlex
W2607486655
Cited by
42
References
54
Citations by year
2025: 3 · 2024: 2 · 2023: 7 · 2022: 5 · 2021: 8 · 2020: 11 · 2019: 4 · 2018: 2
FWCI
1.90
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • World Journal of Gastroenterology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc)
Funders
  • University Hospitals Birmingham NHS Foundation Trust
  • National Institute for Health and Care Research
  • University of Birmingham
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
hepatic steatosis, liver cirrhosis, nonalcoholic steatohepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, hepatic metabolism, branched-chain amino acids, TCA cycle, purine biosynthesis, betaine, propylene glycol, metabolomic biomarkers
MeSH terms
Adult, Aged, Fatty Liver, Female, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Magnetic Resonance Spectroscopy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review